{"id":14741,"date":"2024-10-15T16:44:35","date_gmt":"2024-10-15T16:44:35","guid":{"rendered":"https:\/\/medexperts.pro\/?p=14741"},"modified":"2024-10-15T17:23:42","modified_gmt":"2024-10-15T17:23:42","slug":"could-weight-loss-drugs-help-get-people-back-to-work-the-u-k-wants-to-find-out","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=14741","title":{"rendered":"Could Weight-Loss Drugs Help Get People Back to Work? The U.K. Wants to Find Out."},"content":{"rendered":"
<\/div>\n

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.<\/p>\n

\n
\n
\n

Around one in four adults in Britain is obese, according to estimates from the country\u2019s National Health Service, and the problem costs the public health care system billions every year.<\/p>\n

Now, the government says that weight-loss injections might be part of the solution, and might even help boost Britain\u2019s productivity<\/a>, which has been sluggish for years<\/a>.<\/p>\n

Studies show<\/a> that people with obesity are more likely to find that ill health affects their productivity and attendance at work.<\/p>\n

On Monday, the government announced a <\/em>279 million pound<\/a> (<\/em>around $365 million) investment from the pharmaceutical company Eli Lilly. Among other things, the investment will help explore new ways of delivering health services to people living with obesity, and include a five-year trial of the company\u2019s drug tirzepatide, also known as Mounjaro, which is used to treat diabetes and for weight loss.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

The trial, in the Greater Manchester area in northern England<\/a>, will study the effectiveness of tirzepatide in bringing about weight loss, preventing diabetes and tackling obesity-related health conditions. It will also aim to collect data on whether the drug leads to changes in participants\u2019 employment status and sick days from work, according to a statement<\/a> from the Health Innovation Network, the innovation arm of the N.H.S.<\/p>\n

The government said that up to 3,000 people could eventually take part in the study.<\/p>\n

Prime Minister Keir Starmer, speaking to BBC Breakfast on Tuesday, said he believed the drugs could be \u201cvery important for our economy and for health,\u201d adding that tirzepatide \u201cwill be very helpful to people who want to lose weight, need to lose weight, very important for the economy so people can get back into work.\u201d<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.Around one in four adults in Britain is obese, according to estimates from the country\u2019s National Health Service, and the problem costs the public health care system billions every year.Now, the government says that weight-loss injections might be part of the solution, and might even help boost Britain\u2019s productivity, which has been sluggish for years.Studies show that people with obesity are more likely to find that ill health affects their productivity and attendance at work.On Monday, the government announced a 279 million pound (around $365 million) investment from the pharmaceutical company Eli Lilly. Among other things, the investment will help explore new ways of delivering health services to people living with obesity, and include a five-year trial of the company\u2019s drug tirzepatide, also known as Mounjaro, which is used to treat diabetes and for weight loss.The trial, in the Greater Manchester area in northern England, will study the effectiveness of tirzepatide in bringing about weight loss, preventing diabetes and tackling obesity-related health conditions. It will also aim to collect data on whether the drug leads to changes in participants\u2019 employment status and sick days from work, according to a statement from the Health Innovation Network, the innovation arm of the N.H.S.The government said that up to 3,000 people could eventually take part in the study.Prime Minister Keir Starmer, speaking to BBC Breakfast on Tuesday, said he believed the drugs could be \u201cvery important for our economy and for health,\u201d adding that tirzepatide \u201cwill be very helpful to people who want to lose weight, need to lose weight, very important for the economy so people can get back into work.\u201dWe are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":14743,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[],"class_list":["post-14741","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/14741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14741"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/14741\/revisions"}],"predecessor-version":[{"id":14744,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/14741\/revisions\/14744"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/14743"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}